

Fecha del CVA	24/06/2024
---------------	------------

Parte A. DATOS PERSONALES

Nombre *	Nicolás		
Apellidos *	Merchante Gutiérrez		
Sexo *		Fecha de Nacimiento *	
DNI/NIE/Pasaporte *		Teléfono *	
URL Web			
Dirección Email			
Identificador científico	Open Researcher and Contributor ID (ORCID) *		
	Researcher ID		
	Scopus Author ID		

* Obligatorio

A.1. Situación profesional actual

Puesto			
Fecha inicio	2022		
Organismo / Institución	Servicio Andaluz de Salud		
Departamento / Centro			
País		Teléfono	
Palabras clave			

A.3. Formación académica

Grado/Master/Tesis	Universidad / País	Año
Master en Enfermedades Infecciosas: Actualización en Diagnóstico, Prevención y Tratamiento	Universidad de Sevilla / España	2020
Experto Universitario en Resistencias Microbianas y Optimización del Uso de Antimicrobianos	Universidad de Sevilla	2016
Doctor en Medicina	Departamento de Medicina. Universidad de Sevilla.	2015
Experto Universitario en Infección por el VIH y Enfermedades Asociadas	Universidad de Sevilla	2015
Master Propio en Enfermedades Infecciosas	Universidad de Sevilla	2013
Licenciado en Medicina y Cirugía	Facultad de Medicina. Universidad de Sevilla	2001

A.4. Indicadores generales de calidad de la producción científica

According to Scopus, on 22th February 2024, there are some of my quality data (ORCID 0000-0003-1120-8942):

- H index: 25.
- 2587 total citations.
- 2 papers over 200 citations, 4 papers with over 100 citations and 25 papers with over 30 citations.

Parte C. MÉRITOS MÁS RELEVANTES

C.1. Publicaciones

AC: Autor de correspondencia; (nº x / nº y): posición firma solicitante / total autores. Si aplica, indique el número de citaciones

- 1 **Artículo científico.** (1/6) Merchante N (AC); Herrero R; Valverde-Fredet MD; Rodríguez-Fernández M; Pinagorte H; Martínez-Marcos FJ. 2023. Role of previous systemic antibiotic therapy on the probability of recurrence after an initial episode of Clostridioides difficile infection treated with vancomycin. Journal of Antimicrobial Chemotherapy-Antimicrobial Resistance. 5-2. <https://doi.org/10.1093/jacamr/dlad033>
- 2 **Artículo científico.** Trigo-Rodríguez M; Cárcel S; Navas A; et al; (24/24) Merchante N (AC). 2023. Role of IP-10 to predict clinical progression and response to IL-6 blockade with Sarilumab in early COVID-19 pneumonia. A subanalysis of the SARICOR clinical trial. Open Forum Infectious Diseases. <https://doi.org/10.1093/ofid/ofad133>
- 3 **Artículo científico.** Rodríguez-Fernández M; Gómez RE; Trigo-Rodríguez M; et al; (10/10) Merchante N (AC). 2022. High Incidence of Asymptomatic Phase I IgG Seroconversion After an Acute Q Fever Episode: Implications for Chronic Q Fever Diagnosis. Clinical Infectious Diseases. 74-12, pp.2122-2128. <https://doi.org/10.1093/cid/ciab843>
- 4 **Artículo científico.** (1/1) Nicolás Merchante. 2022. Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial. Antimicrobial Agents and Chemotherapy. 66-2, pp.e0210721. <https://doi.org/10.1128/AAC.02107-21>
- 5 **Artículo científico.** 2021. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA. 326-6, pp.499-518. <https://doi.org/10.1001/jama.2021.11330>
- 6 **Artículo científico.** (1/1) N Merchante. 2020. Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons With Human Immunodeficiency Virus Infection and Compensated Advanced Chronic Liver Disease. Clinical Infectious Diseases. 71-11, pp.2810-2817. <https://doi.org/10.1093/cid/ciz1181>
- 7 **Artículo científico.** (1/1) N Merchante (AC). 2020. Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus infected patients. AIDS. 34-10, pp.1497-1507. <https://doi.org/10.1097/QAD.0000000000002578>
- 8 **Artículo científico.** (1/3) Merchante N; Rodríguez-Fernández M; Pineda JA. 2020. Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. Current HIV/AIDS reports. 17, pp.6-17. ISSN 1548-3568. <https://doi.org/10.1007/s11904-019-00475-0>
- 9 **Artículo científico.** (1/1) Nicolás Merchante (AC). 2019. Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients. AIDS. 33-2, pp.269-278. ISSN 0269-9370. <https://doi.org/10.1097/QAD.0000000000002065>
- 10 **Artículo científico.** (1/23) Merchante N; Saroli Palumbo C; Mazzola G; et al; Sebastiani G. 2019. Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons with HIV infection and Compensated Advanced Chronic Liver Disease. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. ISSN 1058-4838. <https://doi.org/10.1093/cid/ciz1181>
- 11 **Artículo científico.** (1/25) Merchante N (AC); Rodríguez-Arrondo F; Revollo B; et al; GEHEP-002 Study Group. 2018. Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients. AIDS (London, England). 32-11, pp.1423-1430. ISSN 0269-9370. <https://doi.org/10.1097/QAD.0000000000001809>
- 12 **Artículo científico.** (1/17) Merchante N (AC); Rivero-Juárez A; Téllez F; et al; HEPVIR-Cirrhosis Study Group. 2018. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis. The Journal of antimicrobial chemotherapy. ISSN 0305-7453. <https://doi.org/10.1093/jac/dky234>
- 13 **Artículo científico.** (1/16) Nicolás Merchante (AC); Antonio Rivero-Juárez; Francisco Téllez; et al; Juan Antonio Pineda. 2017. Liver stiffness predicts variceal bleeding in HIV/HCV-coinfected patients with compensated cirrhosis. AIDS. 31-4, pp.493-500. <https://doi.org/10.1097/QAD.0000000000001358>

- 14 **Artículo científico.** (1/16) Merchante N (AC); Ibarra S; Revollo B; et al; GEHEP-002 Study Group. 2017. Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients. *AIDS*.
- 15 **Artículo científico.** Ahmet Gorkem Er; Alberto Antonio Romero Alonso; Ignacio Marín-León; et al; Serhat Unal; (12/13) Nicolás Merchante. 2022. Community-acquired pneumonia - An EFIM guideline critical appraisal adaptation for internists. *European Journal of Internal Medicine*. 106, pp.1-8. <https://doi.org/10.1016/j.ejim.2022.10.009>.
- 16 **Artículo científico.** (1/1) Nicolás Merchante (AC). 2022. Impact of COVID19 pandemic on the incidence of health-care associated *Clostridioides difficile* infection. *Anaerobe*. 75, pp.102579. <https://doi.org/10.1016/j.anaerobe.2022.102579>
- 17 **Artículo científico.** 2021. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. *Gut*.
- 18 **Artículo científico.** 2021. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study.
- 19 **Artículo científico.** 2021. Reply to Giannini et al.
- 20 **Artículo científico.** 2021. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19).
- 21 **Artículo científico.** 2020. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain.
- 22 **Artículo científico.** 2020. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
- 23 **Artículo científico.** 2020. Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): Protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial.
- 24 **Artículo científico.** 2020. Recommendations for the diagnosis and treatment of *clostridioides difficile* infection: An official clinical practice guideline of the spanish society of chemotherapy (SEQ), spanish society of internal medicine (SEMI) and the working group of postoperative infection of the spanish society of anesthesia and reanimation (SEDAR), Recomendaciones para el diagnóstico y tratamiento de la infección por *clostridioides difficile*. Guía de práctica clínica de la sociedad española de quimioterapia, sociedad española de medicina interna y grupo de trabajo de infección postoperatoria de la sociedad española de anestesia y reanimación.
- 25 **Artículo científico.** 2020. Similar prevalence of hepatic steatosis among patients with chronic hepatitis C with and without HIV coinfection. *Scientific Reports*. 10-1, pp.6736. <https://doi.org/10.1038/s41598-020-62671-y>
- 26 **Artículo científico.** 2020. Recommendations for the diagnosis and treatment of *Clostridioides difficile* infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR). *Revista Española de Quimioterapia*. 33-2, pp.151-175. <https://doi.org/10.37201/req/2065.2020>
- 27 **Artículo científico.** 2019. Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection. *Journal of Viral Hepatitis*. 26-1, pp.16-24. ISSN 1365-2893. <https://doi.org/10.1111/jvh.12990>
- 28 **Artículo científico.** 2019. Early emergence of opportunistic infections after starting direct-acting antiviral drugs in HIV/HCV-coinfected patients.
- 29 **Artículo científico.** Anaïs Corma Gómez; Juan Macías; Francisco Téllez; et al; Juan A. Pineda; (10/15) Nicolás Merchante. 2019. Liver stiffness at the time of sustained virological response predicts the clinical outcome in HIV/HCV-coinfected patients with advanced fibrosis treated with direct-acting antivirals. *Clinical Infectious Diseases*. Oxford University Press. ISSN 1537-6591. <https://doi.org/10.1093/cid/ciz1140>
- 30 **Artículo científico.** Luis M. Real; Juan Macías; Antonio Rivero Juárez; et al; Juan A. Pineda; (12/15) Nicolás Merchante. 2019. Genetic markers of lipid metabolism genes associated with low susceptibility to HCV infection. *Scientific Reports*. Springer Nature Limited. 9-1, pp.9054. ISSN 2045-2322. <https://doi.org/10.1038/s41598-019-45389-4>

- 31 Artículo científico.** David James Pinato; Elias Allara; Ting-Yi Chen; et al; Norbert Brau; (9/23) Nicolás Merchante. 2018. Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. *Journal of Clinical Oncology*. 37-4, pp.296-304. ISSN 0732-183X. <https://doi.org/10.1200/JCO.18.00885>
- 32 Artículo científico.** Juan A Pineda; B Climent; Federico García; et al; Luis Morano; (9/14) Nicolás Merchante. 2018. Executive summary: Consensus document of GEHEP of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), along with SOCIDROGALCOHOL, SEPD and SOMAPA on hepatitis C virus infection management in drug users. *Enfermedades Infecciosas y Microbiología Clínica*. <https://doi.org/10.1016/j.eimc.2018.09.006>
- 33 Artículo científico.** 2018. Executive summary: Consensus document of GEHEP of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), along with SOCIDROGALCOHOL, SEPD and SOMAPA on hepatitis C virus infection management in drug users. *Enfermedades Infecciosas y Microbiología Clínica*. ISSN 0213-005X. <https://doi.org/10.1016/j.eimc.2018.09.006>
- 34 Artículo científico.** 2018. Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real life. *Scientific Reports*. 8-1, pp.14905. ISSN 2045-2322. <https://doi.org/10.1038/s41598-018-33367-1>
- 35 Artículo científico.** 2018. Executive summary: Consensus document of the diagnosis, management and prevention of infection with the hepatitis E virus: Study Group for Viral Hepatitis (GEHEP) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). *Enfermedades Infecciosas y Microbiología Clínica*. ISSN 0213-005X. <https://doi.org/10.1016/j.eimc.2018.06.014>
- 36 Artículo científico.** 2018. Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort.
- 37 Artículo científico.** Juan Macías; María Mancebo; Dolores Merino; et al; Juan A. Pineda; (10/12) Nicolás Merchante. 2017. Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease. *Clinical Infectious Diseases*. 65-6, pp.1012-1019. <https://doi.org/10.1093/cid/cix467>.
- 38 Artículo científico.** (1/13) Nicolás Merchante (AC); Teresa Aldámiz Echevarría; Monica García Álvarez; et al; Juan A. Pineda. 2017. Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients. *Journal of Viral Hepatitis*. <https://doi.org/10.1111/jvh.12769>
- 39 Artículo científico.** 2017. Low incidence of acute hepatitis C virus infection among Southern Spanish HIV-infected individuals. *Journal of Infection*. <https://doi.org/10.1016/j.jinf.2017.01.013>
- 40 Artículo científico.** 2017. Fat mass and obesity-associated gene variations are related to fatty liver disease in HIV-infected patients. *HIV Medicine*. <https://doi.org/doi:10.1111/hiv.12489>
- 41 Artículo científico.** 2017. Low incidence of acute hepatitis C virus infection among Southern Spanish HIV-infected individuals.
- 42 Artículo científico.** 2017. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
- 43 Artículo científico.** 2016. The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients. *PLoS One*. 11-12, pp.e0168265. <https://doi.org/10.1371/journal.pone.0168265>. [eCollection 2016](#).
- 44 Artículo científico.** Mancebo M; Real LM; Mira JA; et al; Pineda JA. 2016. Changes in the response to treatment against chronic hepatitis C between 1999 and 2015: data from a prospective cohort. *European Journal of Gastroenterology and Hepatology*. 28-11, pp.1253-1257.
- 45 Artículo científico.** Macías J; Monge P; Mancebo M; Merchante N; Neukam K; Real LM; Pineda JA. 2016. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice. *HIV Medicine*.

- 46 Artículo científico.** Macías J; Real LM; Rivero-Juárez A; et al; Pineda JA; (4/9) Merchante N. 2016. Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients. *HIV Medicine*. <https://doi.org/10.1111/hiv.12384>.
- 47 Artículo científico.** Pineda JA; Núñez-Torres R; Téllez F; et al; HEPAVIR Group of The Andalusian Society of Infectious Diseases (SAEI); (6/11) Merchante N. 2015. Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C. *Journal of Infection*. 71-5, pp.571-577. <https://doi.org/10.1016/j.jinf.2015.07.006>
- 48 Artículo científico.** (1/10) Merchante N; Parra-Sánchez M; Rivero-Juárez A; et al; Pineda JA. 2015. High prevalence of antibodies against hepatitis E virus in HIV-infected patients with unexplained liver disease. *Enferm Infecc Microbiol Clin*. 33-8, pp.532-535. <https://doi.org/10.1016/j.eimc.2014.10.018>
- 49 Artículo científico.** Monje-Agudo P; Castro-Iglesias A; Rivero-Juárez A; et al; of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica; (8/17) Merchante N. 2015. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin. *Eur J Clin Microbiol Infect Dis*. 34-10, pp.1929-1936. <https://doi.org/10.1007/s10096-015-2434-6>
- 50 Artículo científico.** Macias J; Rivero-Juarez A; Neukam K; et al; HEPAVIR study group; (7/11) Merchante N. 2015. Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals. *AIDS*. 29-15, pp.1927-1935. <https://doi.org/10.1097/QAD.0000000000000799>
- 51 Artículo científico.** Macías J; Mancebo M; Márquez M; et al; Pineda JA; (9/15) Merchante N. 2015. Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term. *Hepatology*. 61-5, pp.1503-1511. <https://doi.org/10.1002/hep.27674>
- 52 Artículo científico.** (1/16) Merchante N; Téllez F; Rivero-Juárez A; et al; Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermed. 2015. Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis. *BMC Infect Dis*. 15, pp.557. <https://doi.org/10.1186/s12879-015-1291-3>
- 53 Artículo científico.** Guelfo JR; Macias J; Neukam K; et al; Real LM; (6/10) Merchante N. 2014. Reassessment of genotype 1 hepatitis C virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment. *J Clin Microbiol*. 52-11, pp.4027-4029. <https://doi.org/10.1128/JCM.02209-14>
- 54 Artículo científico.** Macías J; Neukam K; (3/4) Merchante N; Pineda JA. 2014. Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients. *Expert Opin Pharmacother*. 15-13, pp.1837-1848. <https://doi.org/10.1517/14656566.2014.934810>
- 55 Artículo científico.** Pineda JA; Cifuentes C; Parra M; et al; Real LM; (4/10) Merchante N. 2014. Incidence and natural history of hepatitis E virus coinfection among HIV-infected patients. *AIDS*. 28-13, pp.1931-1937. <https://doi.org/10.1097/QAD.0000000000000378>
- 56 Artículo científico.** (1/14) Merchante N; Merino E; Rodríguez-Arrondo F; et al; Pineda JA. 2014. HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma. *AIDS*. 28-1, pp.41-47. <https://doi.org/10.1097/QAD.0000000000000005>
- 57 Artículo científico.** Mira JA; Rivero-Juárez A; López-Cortés LF; et al; Grupo Andaluz para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infec; (12/16) Merchante N. 2013. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. *Clinical Infectious Diseases*. 56-11, pp.1646-1653. <https://doi.org/10.1093/cid/cit103>
- 58 Artículo científico.** (1/17) Merchante N; Merino E; López-Aldeguer J; et al; Pineda JA. 2013. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. *Clinical Infectious Diseases*. 56-1, pp.143-150. <https://doi.org/doi:10.1093/cid/cis777>
- 59 Artículo científico.** 2013. Erratum: Coexistence of pyoderma gangrenosum and sweet's syndrome in a patient with ulcerative colitis (*American Journal of Gastroenterology* (2007) 102 (2865-2866) DOI: 10.1111/j.1572-0241.2007.01528-8.x).

- 60 Artículo científico.** Rivero-Juárez A; Camacho A; (3/12) Merchante N; et al; Grupo para el estudio de las hepatitis víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Inf. 2013. Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. *Plos One.* 8-7, pp.e68953. <https://doi.org/10.1371/journal.pone.0068953>
- 61 Artículo científico.** Macías J; Berenguer J; Japón MA; et al; Pineda JA; (12/13) Merchante N. 2012. Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. *Hepatology.* 56-4, pp.1261-1270. <https://doi.org/10.1002/hep.25791>
- 62 Artículo científico.** Neukam K; García-Rey S; Cifuentes C; et al; Pineda JA; (9/11) Merchante N. 2012. HIV-coinfection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection. *Antiviral Res.* 95-3, pp.212-215. <https://doi.org/10.1016/j.antiviral.2012.06.009>
- 63 Artículo científico.** Recio E; Macías J; Rivero-Juárez A; et al; Pineda JA; (11/12) Merchante N. 2012. Liver stiffness correlates with Child-Pugh-Turcotte and MELD scores in HIV/hepatitis C virus-coinfected patients with cirrhosis. *Liver International.* 32-6, pp.1031-1032. <https://doi.org/10.1111/j.1478-3231.2012.02782.x>
- 64 Artículo científico.** (1/14) Merchante N; Rivero-Juárez A; Téllez F; et al; Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermed. 2012. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. *Hepatology.* 56-1, pp.228-238. <https://doi.org/doi:10.1002/hep.25616>
- 65 Artículo científico.** Neukam K; Mira JA; Gilabert I; et al; Pineda JA; (8/11) Merchante N. 2012. Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment. *Eur J Clin Microbiol Infect Dis.* 31-6, pp.1225-1232. <https://doi.org/10.1007/s10096-011-1433-5>
- 66 Artículo científico.** (1/15) Merchante N; López-Cortés LF; Delgado-Fernández M; et al; Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermed. 2011. Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100mg once daily in HIV/hepatitis C virus-coinfected patients. *AIDS Patient Care STDS.* 25-7, pp.395-402. <https://doi.org/10.1089/apc.2011.0109>
- 67 Artículo científico.** Rivero-Juárez A; Mira JA; Pérez-Camacho I; et al; part of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI) (Andalusian Society for Infectious; (8/12) Merchante N. 2011. Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients. *J Antimicrob Chemother.* 66-6, pp.1351-1353. <https://doi.org/10.1093/jac/dkr091>
- 68 Artículo científico.** Macías J; del Valle J; Rivero A; et al; Grupo para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas; (6/13) Merchante N. 2010. Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. *J Antimicrob Chemother.* 65-10, pp.2204-2211. <https://doi.org/10.1093/jac/dkq272>
- 69 Artículo científico.** Pineda JA; Macías J; Mira JA; (4/6) Merchante N; del Valle J; Neukam KI. 2010. HAART and the liver: friend or foe?. *Eur J Med Res.* 15-3, pp.93-96.
- 70 Artículo científico.** Merchante N; Pérez-Camacho I; Mira JA; et al; Grupo Andaluz para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infec. 2010. Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. *Antiviral Therapy.* 15-5, pp.753-763. <https://doi.org/10.3851/IMP1612>
- 71 Artículo científico.** (1/15) Merchante N; Rivero A; de Los Santos-Gil I; et al; Pineda JA. 2009. Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients. *Gut.* 58-12, pp.1654-1660. <https://doi.org/10.1136/gut.2009.179085>
- 72 Artículo científico.** Pineda JA; Aguilar-Guisado M; Rivero A; et al; Grupo para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Inf; (11/13) Merchante N. 2009. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. *Clinical Infectious Diseases.* <https://doi.org/10.1086/605676>
- 73 Artículo científico.** (1/3) Merchante N; Mira JA; Pineda JA. 2009. [Non alcoholic steatosis in HIV infection]. *Medicina Clínica.* 133-3, pp.112-116. <https://doi.org/10.1016/j.medcli.2008.10.033>

- 74 Artículo científico.** (1/12) Merchante N; de los Santos-Gil I; Merino D; et al; Pineda JA. 2009. Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients. *Journal of Hepatology*. 50-4, pp.684-692. <https://doi.org/10.1016/j.jhep.2008.10.032>
- 75 Artículo científico.** Macías J; Palacios RB; Claro E; et al; Pineda JA; (7/9) Merchante N. 2008. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. *Liver International*. 28-6, pp.781-786. <https://doi.org/10.1111/j.1478-3231.2008.01688.x>.
- 76 Artículo científico.** Castro-Fernández M; Sánchez-Muñoz D; Ruíz-Granados E; (4/5) Merchante N; Corzo J. 2007. Coexistence of pyoderma gangrenosum and Sweet's syndrome in a patient with ulcerative colitis. *Am J Gastroenterol*.
- 77 Artículo científico.** Vergara S; Macías J; Mira JA; et al; Pineda JA. 2007. Low-level liver enzyme elevations during HAART are not associated with liver fibrosis progression among HIV/HCV-coinfected patients. *J Antimicrob Chemother*. 59-1, pp.87-91.
- 78 Artículo científico.** (1/3) Merchante N; Jiménez-Saenz M; Pineda JA. 2007. Management of HCV-related end-stage liver disease in HIV-coinfected patients. *AIDS Review*. 9-3, pp.131-139.
- 79 Artículo científico.** (1/10) Merchante N; Macías J; Ramayo E; et al; Pineda JA. 2006. Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-coinfected patients. *Journal of Viral Hepatitis*. 13-7, pp.449-456.
- 80 Artículo científico.** (1/13) Merchante N; Girón-González JA; González-Serrano M; et al; Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. 2006. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. *AIDS*. 20-1, pp.49-57.
- 81 Artículo científico.** Macías J; Mira JA; López-Cortés LF; et al; Pineda JA; (10/15) Merchante N. 2006. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. *Antiviral Therapy*. 11-7, pp.839-846.
- 82 Artículo científico.** Palacios R; (2/10) Merchante N; Macias J; et al; Santos J. 2006. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. *Antiviral Therapy*. 11-4, pp.529-535.
- 83 Artículo científico.** Macias J; Japón MA; Sáez C; et al; Pineda JA; (7/11) Merchante N. 2005. Increased hepatocyte fas expression and apoptosis in HIV and hepatitis C virus coinfection. *The Journal of Infectious Diseases*. 192-9, pp.1566-1576.
- 84 Artículo científico.** García-García JA; Baquerizo R; Vargas J; Mira JA; Merchante N; Macías J; Pineda JA. 2005. [Prevalence of serum antibodies against Bartonella ssp. in a health population from the south area of the Seville province]. *Revista Clínica Española*.
- 85 Artículo científico.** Merchante N; García-García JA; Vergara S; Mira JA; Macías J; Pineda JA. 2004. Bilateral enophthalmos as a manifestation of HIV infection-related lipoatrophy. *HIV Medicine*.
- 86 Artículo científico.** Romero-Gómez M; Ramirez-Martin-Del Campo M; Merchante N; Escalada-Berta J. 2004. Transient Budd-Chiari syndrome due to iatrogenic subcapsular fluid accumulation following thoracocentesis. *American Journal of Gastroenterology*.
- 87 Artículo científico.** Vergara-López S; García-García JA; Merchante N; Mira JA. 2004. [Digoxin toxicity secondary to inhibition of digoxin intestinal metabolism in a patient receiving clarithromycin]. *Medicina Clínica (Barcelona)*.
- 88 Artículo científico.** Merchante N; Macías J; Palacios RB; Mira JA; García-García JA; Lozano F; Pineda JA. 2004. Prevalence of non-significant liver fibrosis and rate of fibrosis progression in HIV/hepatitis C virus- co-infected patients: still a role for liver biopsy?. *AIDS*.
- 89 Artículo científico.** Macías J; Castellano V; (3/10) Merchante N; et al; Pineda JA. 2004. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. *AIDS*. 18-5, pp.767-774.